Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Characterization of antecedent clonal hematopoiesis (CH) mutations in lymphoid and plasma cell neoplasms

Pinkal Desai, Zichan Li, Ying Li, Nuria Mencia-Trinchant, Kathryn Gorski, Wodan Ling, Ellen Ritchie, Michael Samuel, Jonathan Canaani, Michal Bar-Natan, Olivier Elemento, Lesley Tinker, Wendy Cozen, Monica Guzman, Andrea Sboner, Gail Roboz

Blood (2025) 146 (Supplement 1): 1399.

https://doi.org/10.1182/blood-2025-1399

Published: 2025

Journal Articles

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Blood (2025) 146 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2025-1737

Published: 2025

Journal Articles

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Blood (2025) 146 (Supplement 1): 344.

https://doi.org/10.1182/blood-2025-344

Published: 2025

Journal Articles

Disease characteristics and outcomes of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) involvement

Michal Bar-Natan, Sarra Yekta, Justin Kaner, Jonathan Canaani, Pinkal Desai, Ellen Ritchie, Michael Samuel, Hannah Levavi, Eshani Pareek, Debra D'Angelo, Gail Roboz

Blood (2025) 146 (Supplement 1): 1557.

https://doi.org/10.1182/blood-2025-1557

Published: 2025

Journal Articles

Transfusion burden during the initial induction Phase in Acute Myeloid Leukemia is tightly associated with treatment intensity

Jonathan Canaani, Sarra Yekta, John-William Sidhom, Justin Kaner, Ellen Ritchie, Michal Bar-Natan, Michael Samuel, Pinkal Desai, Gail Roboz

Blood (2025) 146 (Supplement 1): 5172.

https://doi.org/10.1182/blood-2025-5172

Published: 2025

Journal Articles

Opening Pandora's Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia

Gail J. Roboz, Nuria Mencia-Trinchant, Gabriela Pereira, Ellen K. Ritchie, Justin D. Kaner, Michael Samuel, Michal Bar-Natan, Jonathan Canaani, Sharmaine Griffith-Baker, Pinkal Desai, Monica L Guzman

Blood (2024) 144 (Supplement 1): 1576.

https://doi.org/10.1182/blood-2024-212090

Published: 2024

Journal Articles

Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia

Juana Martinez, Michelle Becker, Megan Metzger, Nagma Shah, Erin Garbes Feliciano, Alberto Busmail Haylock, Navin Bhatt, Nikolaos Spyrou, John O. Mascarenhas, Douglas Tremblay, Jonathan Feld, Marina Kremyanskaya, Michal Bar-Natan, Hannah Levavi

Blood (2024) 144 (Supplement 1): 2798.

https://doi.org/10.1182/blood-2024-212243

Published: 2024

Journal Articles

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

Blood (2024) 144 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2024-210134

Published: 2024

Journal Articles

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Blood (2024) 144 (Supplement 1): 970.

https://doi.org/10.1182/blood-2024-202365

Published: 2024

Journal Articles

Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy

Blood (2024) 144 (Supplement 1): 1250.

https://doi.org/10.1182/blood-2024-201997

Published: 2024

Journal Articles

Acute Leukemias of Ambiguous Lineage Have Durable Response to Hypomethylating Agents Plus Venetoclax in Older Patients

Joshua A Fein, Sanjay Patel, Neela Easwar, Michal Bar-Natan, Amy Chadburn, Pinkal Desai, Julia Geyer, Michael Kluk, Madhu M Ouseph, Ellen K. Ritchie, Michael Samuel, Paul Simonson, Gail J. Roboz, Justin D. Kaner

Blood (2023) 142 (Supplement 1): 1531.

https://doi.org/10.1182/blood-2023-190532

Published: 2023

Journal Articles

Molecular and Cytogenetic Characteristics of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Patients Exposed to Chemotherapy (CT) and/or Radiation (XRT)

Pinkal Desai, Yasmin Abaza, Hetty E. Carraway, Jason Chua, Michael Samuel, Cynthia Crispino, Bridget Foley, Sindhusha Veeraballi, Peter Doukas, Oluwatobi Odetola, Justin D. Kaner, Michal Bar-Natan, Ellen K. Ritchie, Gail J. Roboz

Blood (2023) 142 (Supplement 1): 821.

https://doi.org/10.1182/blood-2023-190478

Published: 2023

Journal Articles

Array CGH + SNP in ALL Enhances Detection of Complex Cytogenetic Profiles and Suggests That PRSS1 Loss May Play a Role in Leukemogenesis

Hannah Levavi, Daiva Ahire, Yosef Joseph Rene Amel Riazat-Kesh, Tianxiang Sheng, Dahniel L Sastow, Jonathan Feld, Douglas Tremblay, Marina Kremyanskaya, John Mascarenhas, Vesna Najfeld, Michal Bar-Natan

Blood (2023) 142 (Supplement 1): 6062.

https://doi.org/10.1182/blood-2023-185332

Published: 2023

Journal Articles

Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119

Michal Bar-Natan, John Mascarenhas, Aaron T. Gerds, Ruben Mesa, Vikas Gupta, Marina Kremyanskaya, Mikaela Dougherty, Frank Fabris, Kathryn Johnson, Ashley Yu, Heidi E. Kosiorek, Carolyn Mead-Harvey, Amylou C. Dueck, Ronald Hoffman, Raajit K Rampal

Blood (2022) 140 (Supplement 1): 3988–3990.

https://doi.org/10.1182/blood-2022-164678

Published: 2022

Journal Articles

Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification

Metodi Balev, Nicole Zubizarreta, Erin Bresnahan, Jonathan Feld, Marina Kremyanskaya, Alla Keyzner, Alan H. Shih, Bridget K Marcellino, Lewis R. Silverman, Michal Bar-Natan, John Mascarenhas, Douglas Tremblay

Blood (2022) 140 (Supplement 1): 139–140.

https://doi.org/10.1182/blood-2022-167828

Published: 2022

Journal Articles

Central Nervous System Specific Characteristics and Outcomes in Acute Myeloid Leukemia Patients with Neurologic Involvement

Dahniel Sastow, Yosef J.R.A Riazat-Kesh, Kyle Farina, Jonathan Feld, Michal Bar-Natan, Alla Keyzner, Lewis R. Silverman, Marina Kremyanskaya, John Mascarenhas, Douglas Tremblay

Blood (2022) 140 (Supplement 1): 11618–11620.

https://doi.org/10.1182/blood-2022-157300

Published: 2022

Journal Articles

Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures

Alberto Herrera, Anthony Cheng, Eleni P. Mimitou, Angelina Seffens, Dean George, Michal Bar-Natan, Adriana Heguy, Kelly V. Ruggles, Jose U. Scher, Kenneth Hymes, Jo-Ann Latkowski, Niels Ødum, Marshall E. Kadin, Zhengqing Ouyang, Larisa J. Geskin, Peter Smibert, Terkild B. Buus, Sergei B. Koralov

Blood (2021) 138 (16): 1456–1464.

https://doi.org/10.1182/blood.2020009346

Published: 2021

Includes: Supplemental data

Journal Articles

Results of a Phase II Study of PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Gabriela S. Hobbs, MD, Cansu Cimen Bozkus, Martha Wadleigh, MD, Lonette Sandy, Mikaela Doughtery, Kathryn Johnson, Gillian Sanchez, Julia E. Foster, NP, Molly Macrae, Tina T. Som, RN, Michal Bar-Natan, MD, Richard M. Stone, MD, Erin Moshier, MS, Camelia Iancu-Rubin, PhD, John Mascarenhas, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137294

Published: 2020

Journal Articles

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Bridget Marcellino, MD PhD, Joseph Tripodi, Michal Bar-Natan, MD, Harry Fruchtman, Noushin Farnoud, PhD, Min Lu, PhD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Vesna Najfeld, PhD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4207.

https://doi.org/10.1182/blood-2019-129565

Published: 2019

Journal Articles

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Douglas Tremblay, MD, Rafael Madero-Marroquin, MD, Guido Lancman, MD, Alexander Coltoff, MD, Jonathan Feld, MD, Jessica Caro, MD, Nicole Zubizarreta, MPH, Marina Kremyanskaya, Alla Keyzner, MD, Michal Bar-Natan, MD, Shyamala C. Navada, MD, Lewis R. Silverman, Janice L. Gabrilove, MD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 5102.

https://doi.org/10.1182/blood-2019-123288

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Characterization of antecedent clonal hematopoiesis (CH) mutations in lymphoid and plasma cell neoplasms

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Disease characteristics and outcomes of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) involvement

Transfusion burden during the initial induction Phase in Acute Myeloid Leukemia is tightly associated with treatment intensity

Opening Pandora's Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia

Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy

Acute Leukemias of Ambiguous Lineage Have Durable Response to Hypomethylating Agents Plus Venetoclax in Older Patients

Molecular and Cytogenetic Characteristics of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Patients Exposed to Chemotherapy (CT) and/or Radiation (XRT)

Array CGH + SNP in ALL Enhances Detection of Complex Cytogenetic Profiles and Suggests That PRSS1 Loss May Play a Role in Leukemogenesis

Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119

Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification

Central Nervous System Specific Characteristics and Outcomes in Acute Myeloid Leukemia Patients with Neurologic Involvement

Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures

Results of a Phase II Study of PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only